{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "MRK", "name": "Merck & Co., Inc.", "url": "https://frontierpicks.com/dossiers/MRK/", "json_url": "https://frontierpicks.com/dossiers/MRK.json", "status": "WATCHLIST", "current_conviction": "MEDIUM", "archetype": { "code": "a4", "n": 4 }, "current_thesis": "Merck's newer drugs and under-the-skin Keytruda are carrying its growth after raised 2026 guidance on 29 October 2026; the early-February 2027 outlook shows whether moderate growth absorbs over $2 billion of generic losses.", "invalidation_trigger": "A daily close below $138, which would erase the gain since the 2026-10-29 third-quarter report; or 2027 guidance at the fourth-quarter report implying flat or falling sales.", "catalyst_date": "2027-04-22", "portfolio": null, "pick": null, "themes": [ "oncology-immunology", "precision-biotech-therapeutics" ], "tags": [], "sources": [], "caveats": [], "source_links": [ { "title": "Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline", "url": "https://www.businesswire.com/news/home/20261029138599/en/Merck-Co.-Inc.-Rahway-N.J.-USA-Announces-Third-Quarter-2026-Financial-Results-Highlights-Multiple-Milestones-Advancing-Broad-Diverse-Pipeline", "date": "2026-10-29" }, { "title": "Merck (MRK) Q3 2026 Earnings Call Transcript", "url": "https://www.fool.com/earnings/call-transcripts/2026/10/29/merck-mrk-q3-2026-earnings-call-transcript/", "date": "2026-10-29" }, { "title": "Merck Phase 2b MASH Trial: 63% Resolution at 52 Weeks", "url": "https://www.stocktitan.net/news/MRK/merck-announces-positive-results-from-phase-2b-trial-of-82vtypydwucj.html", "date": "2026-11-09" }, { "title": "Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026", "url": "https://www.merck.com/news/merck-to-present-new-data-from-its-broad-oral-hiv-portfolio-and-pipeline-at-hiv-glasgow-2026", "date": null }, { "title": "24/7 Wall St.", "url": "https://247wallst.com/investing/2026/11/03/mercks-pipeline-could-be-its-next-big-growth-driver-its-latest-earnings-offer-a-clue/", "date": "2026-11-03" }, { "title": "merck.com", "url": "https://www.merck.com/news/merck-and-eisai-receive-complete-response-letter-for-keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma/", "date": "2020-07-08" }, { "title": "FDA Accepts NDA for Pimicotinib in Tenosynovial Giant Cell Tumor", "url": "https://www.onclive.com/view/fda-accepts-nda-for-pimicotinib-in-tenosynovial-giant-cell-tumor", "date": null } ], "evidence": [ { "claim": "Third-quarter 2026 revenue was $18.09 billion, against $17.28 billion in the same quarter a year earlier.", "source": "Merck Form 10-Q for the period ended 2026-09-30", "as_of": "2026-11-04" }, { "claim": "Third-quarter 2026 non-GAAP EPS was $2.49, down 3% from $2.58, including a $0.12 per share licensing charge.", "source": "Merck Q3 2026 earnings release (8-K Exhibit 99.1)", "as_of": "2026-10-29" }, { "claim": "Third-quarter sales included a $550 million benefit from customer purchase timing: $200 million Keytruda and $50 million Winrevair reversing in Q4, and $300 million vaccines with $50 million reversing in Q4 and $250 million in 2027.", "source": "Merck Q3 2026 earnings call, CFO Caroline Litchfield", "as_of": "2026-10-29" }, { "claim": "Keytruda/Keytruda Qlex sales were $8.6 billion, up 6%, including $830 million from Keytruda Qlex.", "source": "Merck Q3 2026 earnings release (8-K Exhibit 99.1)", "as_of": "2026-10-29" }, { "claim": "Winrevair sales were $694 million (+93%), Welireg $307 million (+56%), Gardasil/Gardasil 9 $1.995 billion (+14%) and Capvaxive $263 million (+8%) in Q3 2026.", "source": "Merck Q3 2026 earnings release (8-K Exhibit 99.1)", "as_of": "2026-10-29" }, { "claim": "Full-year 2026 sales guidance narrowed to $66.8–67.3 billion from $66.3–67.3 billion; non-GAAP EPS guidance raised to $2.77–2.82 from $2.66–2.76.", "source": "Merck Q3 2026 earnings release (8-K Exhibit 99.1)", "as_of": "2026-10-29" }, { "claim": "Merck expects moderate top-line growth in 2027, partly offset by more than $2 billion of generic headwinds across Bridion, the Januvia family and Adempas, with operating expenses up mid- to high-single digits.", "source": "Merck Q3 2026 earnings call", "as_of": "2026-10-29" }, { "claim": "Efinopegdutide met its Phase 2b primary endpoint in MASH with F2-F3 fibrosis: resolution without fibrosis worsening of 56%, 63% and 61% at 4, 7 and 10 mg versus 13% on placebo at 52 weeks.", "source": "Merck press release, The Liver Meeting 2026 and The Lancet", "as_of": "2026-11-09" } ], "view_changes": [], "frame": null, "filed_numbers": { "as_of": "2026-11-13", "sector": "Healthcare", "financials": { "status": "ok", "reason": null, "close_date": "2026-11-13", "latest_quarter": "2026-09-30", "figures": { "revenue": { "status": "ok", "quarters": [ { "end": "2026-09-30", "filed": "2026-11-04", "restated": null, "value_musd": 18085, "yoy_pct": 4.7 }, { "end": "2026-06-30", "filed": "2026-08-07", "restated": null, "value_musd": 16607, "yoy_pct": 5.1 }, { "end": "2026-03-31", "filed": "2026-05-04", "restated": null, "value_musd": 16286, "yoy_pct": 4.9 }, { "end": "2025-12-31", "filed": "2026-02-24", "restated": null, "value_musd": 16400, "yoy_pct": 5 }, { "end": "2025-09-30", "filed": "2025-11-05", "restated": null, "value_musd": 17276, "yoy_pct": 3.7 }, { "end": "2025-06-30", "filed": "2025-08-05", "restated": null, "value_musd": 15806, "yoy_pct": -1.9 } ] }, "gross_margin": { "status": "ok", "quarters": [ { "end": "2026-09-30", "filed": "2026-11-04", "restated": null, "pct": 72.9 }, { "end": "2026-06-30", "filed": "2026-08-07", "restated": null, "pct": 73.5 }, { "end": "2026-03-31", "filed": "2026-05-04", "restated": null, "pct": 74.2 }, { "end": "2025-12-31", "filed": "2026-02-24", "restated": null, "pct": 66.2 }, { "end": "2025-09-30", "filed": "2025-11-05", "restated": null, "pct": 77.7 }, { "end": "2025-06-30", "filed": "2025-08-05", "restated": null, "pct": 77.5 } ] }, "operating_margin": { "status": "not reported" }, "pretax_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 5559 }, "net_income": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "four_quarters_end": "2026-09-30", "value_musd": 5065, "four_quarters_musd": 2453 }, "operating_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "first_end": "2025-12-31", "value_musd": 18703 }, "capital_spending": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "first_end": "2025-12-31", "value_musd": 3957 }, "free_cash_flow": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "first_end": "2025-12-31", "value_musd": 14746 }, "diluted_share_change": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "base_end": "2025-09-30", "pct": -0.8 }, "cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 9650 }, "debt": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 53800 }, "net_cash": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": -44150 }, "deferred_revenue": { "status": "not reported" }, "backlog": { "status": "not reported" }, "receivables": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 12744 }, "inventory": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 6164 }, "equity": { "status": "ok", "end": "2026-09-30", "filed": "2026-11-04", "value_musd": 44893 }, "market_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-31", "basis_filed": "2026-11-04", "value_musd": 364264.7 }, "enterprise_value": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-31", "basis_filed": "2026-11-04", "value_musd": 408414.7 }, "ev_sales": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-31", "basis_filed": "2026-11-04", "multiple": 6.1 }, "ev_ebit": { "status": "not available" }, "pe": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-31", "basis_filed": "2026-11-04", "multiple": 148.5 }, "pb": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-31", "basis_filed": "2026-11-04", "multiple": 8.1 }, "fcf_yield": { "status": "ok", "close_date": "2026-11-13", "basis_end": "2026-10-31", "basis_filed": "2026-11-04", "pct": 4 } } }, "short_interest": { "status": "ok", "settlement": "2026-10-15", "published": "2026-10-26", "short_pct_of_outstanding": 1.09, "days_to_cover": 3, "change_pct": -5.1 }, "insiders": { "status": "ok", "as_of": "2026-11-15", "windows": [ { "days": 90, "status": "ok", "from": "2026-08-18", "bought_usd": 0, "sold_usd": 0, "bought_unpriced": 0, "sold_unpriced": 0 }, { "days": 365, "status": "ok", "from": "2025-11-16", "bought_usd": 0, "sold_usd": 70677185.69, "bought_unpriced": 0, "sold_unpriced": 0 } ] } }, "body_markdown": "## Current Thesis\nMerck's newer drugs and the under-the-skin form of Keytruda are carrying its growth, as the third-quarter results and raised 2026 guidance of 2026-10-29 showed. The first 2027 guidance, expected with the fourth-quarter report in early February 2027, will show whether management's \"moderate\" growth outlook can absorb more than $2 billion of generic losses before Keytruda's US patent expires in 2028.\n\nThe rating is Medium. The business numbers point up, but the deciding figure, 2027 sales guidance, will not be published until February. The quarterly report filed with the SEC on 2026-11-04 shows third-quarter revenue of $18.09 billion, against $17.28 billion a year earlier. Management raised its full-year earnings guidance the same quarter.\n\nThe price already reflects the raised 2026 outlook. The shares closed at $147.18 on 2026-11-11. That is 6.2% below the 52-week intraday high of $156.92 from 2026-08-25 and well above the 52-week closing low of $90.95 from 2025-11-11. The 2027 outlook is the part the market has not yet been able to price.\n\nThe pipeline news since the report has come from outside the 2027 numbers. On 2026-11-09 Merck said efinopegdutide met its main goal in a Phase 2b trial in metabolic dysfunction-associated steatohepatitis (MASH), a fatty-liver disease that scars the liver. The HIV Glasgow meeting ended on 2026-11-11. There Merck presented subgroup analyses of its once-weekly islatravir/lenacapavir pill, which it plans to file with regulators.\n\n## Bull Case\n- **Keytruda is still growing.** Keytruda and Keytruda Qlex sales rose 6% to $8.6 billion in the third quarter, per Merck's 2026-10-29 release. Qlex, the under-the-skin form, contributed $830 million.\n- **Qlex conversion has a stated goal.** On the 2026-10-29 earnings call, oncology president Johannes Oosthuizen said Merck feels good about reaching 30% to 40% of US Keytruda use on Qlex by the end of 2027. A high share before the 2028 patent expiry is what makes the switch valuable.\n- **Winrevair and Welireg are scaling.** Winrevair, which treats high blood pressure in the lungs, rose 93% to $694 million in the third quarter. Welireg rose 56% to $307 million, and Gardasil rose 14% to $1.995 billion, per the 2026-10-29 release.\n- **2026 guidance went up.** Merck narrowed its 2026 sales guidance to $66.8–67.3 billion from $66.3–67.3 billion. It raised non-GAAP earnings per share (EPS) guidance to $2.77–2.82 from $2.66–2.76, per the 2026-10-29 release.\n- **The liver-disease drug cleared Phase 2b.** At 52 weeks, 56%, 63% and 61% of patients on the 4 mg, 7 mg and 10 mg doses of efinopegdutide had their MASH resolve without worse liver scarring. The rate on placebo was 13%, per Merck's 2026-11-09 release, with the results published in The Lancet the same day.\n- **Two FDA decisions are dated.** The US Food and Drug Administration (FDA) set a 2027-06-15 decision date for sacituzumab tirumotecan (sac-TMT) in previously treated endometrial cancer, per the 2026-10-29 release. Merck said on 2026-11-02 that the FDA set a 2027-04-22 action date for Idvynso (doravirine/islatravir) applications, including adults starting HIV treatment.\n- **An analyst raised his target after the report.** Daiwa Securities raised its price target to $160 from $143 on 2026-11-04, per Fiscal.ai.\n\n## Bear Case\n- **Third-quarter sales included timing gains.** On the 2026-10-29 call, Chief Financial Officer Caroline Litchfield said $550 million of third-quarter sales came from when customers placed orders. Of that, $200 million of Keytruda and $50 million of Winrevair reverse in the fourth quarter, and $250 million of vaccines reverse in 2027.\n- **Generic losses arrive in 2027.** Management said on the 2026-10-29 call that more than $2 billion of generic losses across Bridion, the Januvia family and Adempas will partly offset 2027 growth. It expects operating expenses to rise by a mid- to high-single-digit percentage.\n- **Third-quarter EPS fell.** Non-GAAP EPS was $2.49, down 3% from $2.58 a year earlier, including a $0.12 per share licensing charge, per the 2026-10-29 release.\n- **Capvaxive growth has slowed.** Sales of the adult pneumococcal vaccine grew 8% to $263 million in the third quarter, per the 2026-10-29 release. That is far below the pace of Merck's other newer products.\n- **Qlex faces patent lawsuits.** Halozyme is suing over the under-the-skin Keytruda in Europe, including in a court in The Hague, and in US federal court in New Jersey. A loss would slow the switch Merck is counting on before 2028.\n- **Some forecasters see the price as full.** 24/7 Wall St. set a 12-month target of $124.70 with a Hold rating on 2026-11-03, after the third-quarter beat.\n\n## Setup & Price Structure\nThe shares closed at $147.18 on 2026-11-11, per daily closes. The 50-day moving average is $146.18 and the 200-day moving average is $127.14, both as of that close. The shares are up 9.2% over three months.\n\nSince the 2026-11-04 close of $150.36, the shares have traded in a narrow range. They closed at $146.73 on 2026-11-06 and $148.76 on 2026-11-09. They sit just above the 50-day average and 6.2% below the 52-week high of $156.92 from 2026-08-25.\n\nThe 50-day average is the nearest level the case turns on. A sustained move below it would show the post-report gain fading before the February guidance. A close back above the August high would show the market pricing 2027 growth before management states it.\n\n## Catalyst Calendar\n\n- **~2027-02-01 (est.):** CMS list of drugs selected for the next Medicare price-negotiation cycle. Shows whether Keytruda is selected and whether the under-the-skin Qlex form is treated with it, which sets how much US pricing pressure follows the 2028 patent expiry.\n- **~2027-02-03 (est.):** Fourth-quarter 2026 report and first 2027 guidance. Puts a number on the moderate 2027 growth management described against more than $2 billion of generic losses, and shows Keytruda and Winrevair sales after the flagged purchase-timing reversal.\n- **2027-04-22:** FDA action date for Idvynso supplemental applications, including treatment-naive adults. A wider label would open the larger first-treatment HIV market to Merck's two-drug regimen.\n- **2027-06-15:** FDA decision date for sac-TMT in previously treated endometrial cancer. First US approval for the antibody-drug conjugate Merck needs as an oncology growth driver after Keytruda.\n\n## What Would Change Our Mind\n\nA daily close below $138, which would erase the gain since the 2026-10-29 third-quarter report; or 2027 guidance at the fourth-quarter report implying flat or falling sales.\n\nThe risks this note tracks, each with what would confirm it:\n\n- Keytruda growth stalls before newer products are large enough to replace it ahead of its 2028 US patent expiry. Confirmed by: Keytruda/Keytruda Qlex sales falling year over year at the fourth-quarter 2026 report by more than the $200 million purchase-timing reversal management flagged.\n- 2027 guidance shows generic losses and rising operating costs outweighing growth from newer products. Confirmed by: A 2027 sales range at the early-February report that implies flat or lower sales than 2026.\n- Capvaxive's US slowdown deepens on lower adult pneumococcal vaccination rates and net pricing. Confirmed by: Capvaxive sales falling year over year in the fourth-quarter 2026 report.\n- Halozyme's patent cases limit the shift of patients to Keytruda Qlex before the core patents expire. Confirmed by: A US court ruling against Merck in Halozyme's New Jersey case, or injunctions extending beyond the six European markets Merck named on 2026-10-29.\n- Efinopegdutide's tolerability or comparison with semaglutide falls short of what a Phase 3 program needs. Confirmed by: Merck declining to start Phase 3, or full semaglutide-arm data showing similar efficacy with better tolerability than efinopegdutide.\n- PD-1/VEGF drugs such as ivonescimab take share from Keytruda in lung cancer. Confirmed by: Phase 3 head-to-head results showing a PD-1/VEGF drug beating Keytruda-based treatment, or US filings built on such results.\n\n## Correlation Notes\nMerck trades with large US drugmakers and with defensive health-care stocks. Those can lag when investors favour growth or cyclical sectors, as Benzinga reported on 2026-11-06 and 2026-11-11 when defensives trailed. US drug-pricing policy moves the whole group: Benzinga reported on 2026-11-11 that pricing pressure from Washington was rising for Lilly and Gilead.\n\nNews about Merck's partners moves Merck too. Intismeran autogene is shared with Moderna. Merck licensed sac-TMT from Kelun-Biotech and efinopegdutide from Hanmi Pharmaceutical. Halozyme is on the other side of the Qlex patent cases.\n\nThe name is often confused. Headlines on 2026-11-10 about the FDA approval of pimicotinib (Pimjetmi) for tenosynovial giant cell tumor concern Germany's Merck KGaA, not Merck & Co. A 2026-11-09 news-feed item about a complete response letter (an FDA rejection) for Keytruda plus Lenvima in first-line liver cancer repeats a July 2020 decision, per Merck's press release of 2020-07-08.", "first_seen": "2026-11-10", "last_analyzed": "2026-11-12T04:09:55+00:00", "last_synthesized": "2026-11-12", "date_modified": "2026-11-12", "license": "Content © FrontierPicks. Cite the canonical URL." }